Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5
- Authors
- 김형돈; 임현수; 김좌훈; 정혜현; 윤신교; 박인근; 이재련
- Issue Date
- Oct-2021
- Publisher
- 대한암학회
- Keywords
- Urothelial carcinoma; Gemcitabine plus carboplatin; Glomerular filtration rate; Objective response rate
- Citation
- Cancer Research and Treatment, v.53, no.4, pp.1166 - 1173
- Journal Title
- Cancer Research and Treatment
- Volume
- 53
- Number
- 4
- Start Page
- 1166
- End Page
- 1173
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83401
- DOI
- 10.4143/crt.2021.091
- ISSN
- 1598-2998
- Abstract
- Purpose This study aimed to investigate the clinical outcomes with gemcitabine-carboplatin (GCb), the standard treatment for patients with advanced urothelial carcinoma (UC) who are ineligible for cisplatin-based regimens, in advanced UC patients with a glomerular filtration rate (GFR) < 30 mL/min.
Materials and Methods A retrospective cohort study involving GCb-treated advanced UC patients with GFR < 60 mL/min (n=89) was performed. Clinical outcomes were compared between subgroups with GFR < 30 mL/min and GFR ≥ 30 mL/min but < 60 mL/min.
Results Most baseline characteristics were comparable between the two subgroups. Patients with GFR < 30 mL/min had a significantly lower objective response rate (12.5%) compared to those with higher GFR levels (56.7%) (p=0.004). The number of GCb cycles was significantly lower in patients with GFR < 30 mL/min (median 2 cycles) than in those with higher GFR levels (median 6 cycles) (p=0.002). Compared to those with GFR ≥ 30 mL/min but < 60 mL/min, patients with GFR < 30 mL/min showed significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.001 for both). Further stratification of patient subgroups according to their GFR (i.e., GFR ≥ 45 mL/min but < 60 mL/min vs. GFR ≥ 30 mL/min but < 45 mL/min vs. GFR < 30 mL/min) revealed significantly different PFS and OS (p < 0.001 for both).
Conclusion The use of GCb is discouraged in advanced UC patients with GFR < 30 mL/min. Alternative therapeutic approaches with better efficacy are warranted for these patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83401)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.